What does this research mean for the field?

Zorevunersen shows a favorable safety profile and initial clinical improvement as a potential disease-modifying treatment for Dravet syndrome in children and adolescents. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Assess the safety and clinical efficacy of zorevunersen for treating Dravet syndrome in youth.

March 7, 2026New England Journal of Medicine1 citations

View Full Paper

Zorevunersen in Children and Adolescents with Dravet Syndrome

LLLinda C. LauxRobert H. Lurie Comprehensive Cancer Center of Northwestern University JSJoseph SullivanUCSF Benioff Children's Hospital MPM. Scott PerryCook Children's Medical Center

Key Points

Assess the safety and clinical efficacy of zorevunersen for treating Dravet syndrome in youth.
Conducted clinical trials (NCT04442295, NCT04740476)
Evaluated safety profile and clinical improvement metrics
Involved children and adolescents with Dravet syndrome
Demonstrated a favorable safety profile for zorevunersen
Reported initial clinical improvements in treated patients
Support for continued development of zorevunersen as a treatment option

Abstract

The safety profile and initial clinical improvement support the continued development of zorevunersen as a potential disease-modifying treatment for Dravet syndrome. (Supported by Stoke Therapeutics; MONARCH and SWALLOWTAIL ClinicalTrials.gov numbers, NCT04442295 and NCT04740476, respectively; ADMIRAL and LONGWING ISRCTN Registry numbers, ISRCTN99651026 and ISRCTN12811235, respectively.).

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Zorevunersen in Children and Adolescents with Dravet Syndrome

Key Points

Abstract

Cite This Study

Also Consider

Also Consider